Skip to content

Oesophago-gastric Cancer Research

Cancer ResearchAmplification frequency and prognostic value of key receptor tyrosine kinase signalling genes in oesophago-gastric cancer – working towards a biomarker driven, multi-targeted agents trial to improve clinical outcome

Oesophago-gastric cancer is the second most common cause of cancer death worldwide. Conventional chemotherapy is able to significantly extend patient survival when given before and after surgery. Chemotherapy can also increase survival in patients who present with very advanced metastatic disease. However, chemotherapy options for patients with oesophago-gastric cancer are much more limited compared to what is offered to patients with other cancers. The current project aims to determine whether patients with oesophago-gastric cancer might benefit from so called ‘targeted agents’ which appear to be only effective if the tumour cells carry the ‘target’ gene mutations.


  • Principle investigator: Professor Phil Quirke
  • University of Leeds
  • Award amount: £182,801
  • August 2013 – July 2017